Related Experiment Video
Updated: Aug 4, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC
Haoming Wu1,2, Jikun Feng1, Wenjing Zhong1
1Department of Breast Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Introduction:
Compared to other types of breast cancer, triple-negative breast cancer (TNBC) does not effectively respond to hormone therapy and HER2 targeted therapy, showing a poor prognosis. There are currently a limited number of immunotherapeutic drugs available for TNBC, a field that requires additional development.
Methods:
Co-expressing genes with M2 macrophages were analyzed based on the infiltration of M2 macrophages in TNBC and the sequencing data in The Cancer Genome Atlas (TCGA) database. Consequently, the influence of these genes on the prognoses of TNBC patients was analyzed. GO analysis and KEGG analysis were performed for exploring potential signal pathways. Lasso regression analysis was conducted for model construction. The TNBC patients were scored by the model, and patients were divided into high- and low-risk groups. Subsequently, the accuracy of model was further verified using GEO database and patients information from the Cancer Center of Sun Yat-sen University. On this basis, we analyzed the accuracy of prognosis prediction, correlation with immune checkpoint, and immunotherapy drug sensitivity in different groups.
Results:
Our findings revealed that OLFML2B, MS4A7, SPARC, POSTN, THY1, and CD300C genes significantly influenced the prognosis of TNBC. Moreover, MS4A7, SPARC, and CD300C were finally determined for model construction, and the model showed good accuracy in prognosis prediction. And 50 immunotherapy drugs with therapeutic significance in different groups were screened, which were assessed possible immunotherapeutics that have potential application and demonstrated the high precision of our prognostic model for predictive analysis.
Conclusion:
MS4A7, SPARC, and CD300C, the three main genes used in our prognostic model, offer good precision and clinical application potential. Fifty immune medications were assessed for their ability to predict immunotherapy drugs, providing a novel approach to immunotherapy for TNBC patients and a more reliable foundation for applying drugs in subsequent treatments.
Insights
Triple-negative breast cancer (TNBC) has a poor prognosis. Researchers identified MS4A7, SPARC, and CD300C genes to predict TNBC patient outcomes and screened 50 immunotherapy drugs for potential treatments.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited treatment options.
- Current immunotherapies for TNBC are restricted, highlighting the need for novel therapeutic strategies and predictive biomarkers.
Purpose of the Study:
- To identify key genes associated with M2 macrophage infiltration in TNBC.
- To develop a prognostic model for TNBC patients based on identified genes.
- To explore potential immunotherapy drug sensitivity in different risk groups.
Main Methods:
- Analysis of gene co-expression with M2 macrophages using TCGA and GEO databases.
- Gene Ontology (GO) and KEGG pathway analysis.
- Lasso regression for prognostic model construction and validation.
- Screening of immunotherapy drugs based on patient risk stratification.
Main Results:
- Identified OLFML2B, MS4A7, SPARC, POSTN, THY1, and CD300C as significantly influencing TNBC prognosis.
- Developed a prognostic model using MS4A7, SPARC, and CD300C with high predictive accuracy.
- Screened 50 immunotherapy drugs, assessing their potential therapeutic significance in different risk groups.
Conclusions:
- The prognostic model based on MS4A7, SPARC, and CD300C demonstrates high precision and clinical applicability for TNBC.
- The identification of potential immunotherapy drugs offers a novel approach for treating TNBC patients.
- This study provides a foundation for personalized immunotherapy strategies in TNBC.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy